JP Morgan Chase
CABA icon

JP Morgan Chase’s Cabaletta Bio CABA Stock Holding History

JP Morgan Chase’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$185K Buy
59,368
+52,162
+724% +$172K ﹤0.01% 5664
2026
Q1 		$17.8K Sell
7,206
-2,599
-27% -$7.22K ﹤0.01% 6585
2025
Q4 		$21.5K Sell
9,805
-527,844
-98% -$1.31M ﹤0.01% 6487
2025
Q3 		$1.26M Buy
537,649
+456,853
+565% +$784K ﹤0.01% 4420
2025
Q2 		$123K Sell
80,796
-170,641
-68% -$266K ﹤0.01% 5511
2025
Q1 		$348K Sell
251,437
-7,955
-3% -$16.9K ﹤0.01% 4985
2024
Q4 		$589K Sell
259,392
-20,562
-7% -$72.2K ﹤0.01% 4952
2024
Q3 		$1.32M Sell
279,954
-676,735
-71% -$3.92M ﹤0.01% 4298
2024
Q2 		$7.16M Buy
956,689
+933,034
+3,944% +$11.4M ﹤0.01% 2765
2024
Q1 		$404K Sell
23,655
-21,185
-47% -$455K ﹤0.01% 4940
2023
Q4 		$1.02M Buy
44,840
+21,172
+89% +$356K ﹤0.01% 4321
2023
Q3 		$360K Buy
23,668
+3,204
+16% +$43.8K ﹤0.01% 4676
2023
Q2 		$264K Buy
20,464
+19,831
+3,133% +$215K ﹤0.01% 4911
2023
Q1 		$5K Hold
633
– – ﹤0.01% 6238
2022
Q4 		$6K Sell
633
-1,276
-67% -$4.65K ﹤0.01% 6117
2022
Q3 		$1K Buy
1,909
+311
+19% +$374 ﹤0.01% 6303
2022
Q2 		$2K Sell
1,598
-2,110
-57% -$2.98K ﹤0.01% 6273
2022
Q1 		$8K Buy
3,708
+849
+30% +$2.22K ﹤0.01% 6242
2021
Q4 		$11K Sell
2,859
-15,346
-84% -$164K ﹤0.01% 6317
2021
Q3 		$221K Buy
18,205
+5,603
+44% +$51.7K ﹤0.01% 5176
2021
Q2 		$108K Sell
12,602
-17,895
-59% -$176K ﹤0.01% 5512
2021
Q1 		$339K Buy
30,497
+4,575
+18% +$55.9K ﹤0.01% 4899
2020
Q4 		$323K Buy
25,922
+7,794
+43% +$101K ﹤0.01% 4614
2020
Q3 		$189K Buy
18,128
+3,093
+21% +$35.5K ﹤0.01% 4385
2020
Q2 		$167K Buy
15,035
+1,574
+12% +$12.1K ﹤0.01% 4344
2020
Q1 		$98K Buy
13,461
+11,336
+533% +$155K ﹤0.01% 4514
2019
Q4 		$30K Buy
+2,125
New +$25.2K ﹤0.01% 5250

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

JP Morgan Chase's CABA Position: Q2 2026 in Review

JP Morgan Chase increased its Cabaletta Bio (CABA) stake by 724% in Q2 2026, buying an estimated $172K and bringing the position to 59,368 shares worth $185K. The position accounts for ﹤0.01% of the portfolio, ranked #5664.

JP Morgan Chase first reported a position in CABA in Q4 2019 and has held it in 27 quarters since. The position peaked at $7.16M in Q2 2024. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • JP Morgan Chase held 59,368 shares of Cabaletta Bio worth $185K as of Q2 2026.
  • JP Morgan Chase bought 52,162 Cabaletta Bio shares in Q2 2026, an estimated $172K.
  • Cabaletta Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5664 holding.
  • JP Morgan Chase first reported a position in Cabaletta Bio in Q4 2019 and has held it in 27 quarters since.
  • JP Morgan Chase's Cabaletta Bio position peaked at $7.16M in Q2 2024.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.